Mini Review

Cognitive frailty: a brief review

Evangelia Petridou¹,²

¹Postgraduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Athens, Greece; ²“Korgialenio-Benakio” General Hospital, Ampelokipoi, Athens, Greece

Abstract
Frailty syndrome and cognitive decline, conditions linked with aging, jeopardize health status and promote an individual’s dependence on daily living activities. Various models include cognition in the assessment of frailty, but recently a new term has been proposed, called “Cognitive Frailty”, originally presented as a probable outcome of frailty, but later it has been proposed to be an early sign of the syndrome. Cognitive frailty encompasses both the physical and the cognitive domain, explored as a unique entity, and includes two subtypes, the reversible and the potentially reversible cognitive frailty. Most studies examine cognition as another domain of frailty, using different methods for the assessment of both frailty and the status of cognition. In the present article, various definitions of the frailty syndrome and cognitive frailty as well as screening tools are reviewed. The link between cognitive impairment and frailty, and the common pathophysiological mechanisms such as neuropathological, vascular and metabolic factors, inflammation, hormones and nutrition are explored. Finally, this review presents the effects of multi-domain and single domain interventions, conducted in physical and/or cognitively frail populations that may be applied to the prevention and management of cognitive frailty.

Keywords: Cognition, Cognitive Frailty, Frailty Syndrome

Introduction
The frailty syndrome has received numerous attention over the years due to its consequences to adverse health outcomes, and relationship to aging, as indicated by various studies. Frailty is different from comorbidity and disability, but extends to both and vice versa¹. The health outcomes may be detrimental and include falls, disability, hospitalization, and early mortality. For example, in a cohort study that examined institutionalized people, it was found that it is 3.3 times more probable that frail older adults will be disabled or dead in a year follow up². In community dwelling people, the results of a meta-analysis reflected the higher probability of falls in frail, primarily, and pre-frail, secondly, older adults³. In addition to the previous study the community based Health and Retirement Study (HRS) displayed that frail and cognitively impaired individuals are prone to develop future disability expressed as dependence on activities of daily living (ADL dependence)-and death⁴. Furthermore, the level of frailty jeopardizes the elderly in the concept of making them susceptible to falls, dependence, institutionalization and death⁵.

Besides the occurrence of death, frailty and its consequences have a large impact on Quality of Life (QoL). This concept is in accordance with the results of a study that demonstrates that older frail persons perceive their QoL as substantially lower, in comparison with their pre-frail and non-frail counterparts⁶. There is a link between aging, frailty and cognitive decline. Frailty is ascribed to various hazardous factors, age being one of them⁷. Consequently, older people are more likely to become frail⁸. Age also was associated with a rapid rate of physical frailty related-cognitive decline⁹, and was determined a crucial factor in dementia because it contributes to the progression from Mild Cognitive Impairment (MCI) to the former¹⁰. Thus, it is the current trade to scrutinize MCI¹¹ in the light of frailty, something that may indicate the increasing prevalence of cognitive frailty during the aging process¹².

The author has no conflict of interest.

Corresponding author: Evangelia Petridou, Postgraduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Mikras Asias 75, 11527, Goudi, Athens, Greece
E-mail: evelynpetridou@gmail.com
Edited by: Konstantinos Stathopoulos
Accepted 19 December 2019

10.22540/JRPMS-04-113
Regarding the question “what is frailty syndrome?” researchers haven’t reached an accord pertaining to a common well accepted definition, thus there are several of them originated by the various frailty models respectively. In 2001, Fried et al. (2001) described frailty as a clinical syndrome, in which a person is vulnerable to acute stressors due to age related decline, both functional and in reserve, across multiple physiologic systems, resulting in an inability to maintain a stable homeostasis. She proposed a definition based on Frailty Phenotype, characterized by the presence of at least three out of five criteria: unintentional weight loss, self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity. Conversely, the accumulation of one or two criteria identifies a pre-frail state that presents a high risk for frailty. However this model does not take into account the psychological, cognitive, and social domain in the screening for frailty. On the contrary Rockwood et al. (2005) approached frailty from a multidimensional angle, applying both physical and cognitive origins to the frailty syndrome. Therefore a new definition of frailty was put forward based on a deficits accumulation such as unhealthy behaviour, signs and symptoms, laboratory data, comorbidity, and self-reported disabilities, whose screening tool is Frailty Index (FI), representing the total sum of deficits present on a person, that add up to 70. For example, when a person gathers 10 deficits out of 50 it results to a FI $10/50=0.20^{12,13}$ (Figure 1).

On the other hand R.J. Gobbens et al. (2010) proposed the integral conceptual definition by which frailty was discerned as a dynamic state impacting on a human being who endures losses: a) concerning the physical, psychological including cognition, and social realm and b) are attributable to a range of variables, consequently leading to poor probabilities for adverse outcomes. This model uses The Tilburg Frailty Index (TFI) a questionnaire that identifies frail older subjects, the severity of the syndrome and the specific frailty domain. Table 1).

Inevitably over the years many researchers have been involved in the study of frailty, therefore proposing definitions, measure tools and scales that differ between them. Despite the lack of agreement among the scientific community, a new entity appeared called cognitive frailty, that applied to both physical and cognitive decline, on account of the increasing interest and thought-provoking findings related to the cognitive defaults accompanying frailty.

### Cognitive frailty

According to the International Academy on Nutrition and Aging (IANA) and the International Association of Gerontology and Geriatrics (IAGG) (IANA/IAGG), an international consensus group, cognitive frailty indicates the concurrent clinical presence of both physical frailty and also of cognitive impairment. Specifically, this condition requires the co-existence of both physical frailty and cognitive impairment with a Clinical Dementia Rating (CDR) equal to 0.5 and the

---

**Figure 1. The Frailty Index (FI) algorithm.**

**Table 1.** The Tilburg Frailty Index (TFI).

| Frailty domains | Frailty components |
|-----------------|--------------------|
| Physical:       | Unintended weight loss, walking difficulties, grip strength, fatigue, balance, sight and hearing loss |
| Psychological:  | Cognitive functions, depression symptoms, anxiety, activities of daily living |
| Social:         | Living alone, social relations, supportive environment |

---

**Domains of frailty**

Regarding the question “what is frailty syndrome?” researchers haven’t reached an accord pertaining to a common well accepted definition, thus there are several of them originated by the various frailty models respectively. In 2001, Fried et al. (2001) described frailty as a clinical syndrome, in which a person is vulnerable to acute stressors due to age related decline, both functional and in reserve, across multiple physiologic systems, resulting in an inability to maintain a stable homeostasis. She proposed a definition based on Frailty Phenotype, characterized by the presence of at least three out of five criteria: unintentional weight loss, self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity. Conversely, the accumulation of one or two criteria identifies a pre-frail state that presents a high risk for frailty. However this model does not take into account the psychological, cognitive, and social domain in the screening for frailty. On the contrary Rockwood et al. (2005) approached frailty from a multidimensional angle, applying both physical and cognitive origins to the frailty syndrome. Therefore a new definition of frailty was put forward based on a deficits accumulation such as unhealthy behaviour, signs and symptoms, laboratory data, comorbidity, and self-reported disabilities, whose screening tool is Frailty Index (FI), representing the total sum of deficits present on a person, that add up to 70. For example, when a person gathers 10 deficits out of 50 it results to a FI $10/50=0.20^{12,13}$ (Figure 1).
exclusion of all types of dementia. Still, in a different situation cognitive frailty may signal a neurodegenerative process. A recognizable psychological element contributes to making the individual more vulnerable to stressors. The consensus group was exclusively interested in discussing cognitive decline and the existing evidence as a potential outcome of physical frailty and not the reverse, accounting to the already well known underlying neurodegenerative pathways.

Contrary to IANA/IAGG, cognitive frailty may be defined by the co-occurrence of cognitive impairment and a pre-frailty status rather than frailty. In support to this study cognitive frailty was defined as the presence of both cognitive impairment in any domain and dynapenia expressed by slowness and/or weakness, both part of Fried’s criteria for frailty that represent a decrease in muscle strength and physical ability (Table 2).

There aren’t many studies referring to the prevalence of cognitive frailty (CF), as frailty and cognitive impairment is only recently explored as a unique entity. The combined prevalence of frailty and MCI was found 2.7% in a later study and Liu et al. (2018) presented a percentage of 13.3%. Sex (women) were indicative of CF status and living in rural rather, than urban areas.

### Stages of cognitive decline

The stages of cognitive decline are presented in Figure 2. Mild Cognitive Impairment (MCI) stands between normal cognition and clinically probable Alzheimer’s disease. In 2003 a first key symposium was held by the International Working Group on Mild Cognitive Impairment and a consensus was reached in recommendations for the general MCI criteria including the following: a) absence of normal cognition as well as dementia, b) self/informant reported evidence of cognitive decay, and/or objective decline on cognitive tasks over time and c) the person preserves basic activities of daily living and is able to function at least adequately in complex tasks. MCI was further classified into three subtypes: amnestic, multiple domain, and single non-memory domain MCI.

A grey zone exists between normal status and MCI that may be indicating a pre-MCI state, called Subjective Cognitive Decline (SCD). Usually cognitive impairment comes from a gradual development of a neurodegenerative disease until it comes to the point where a deficit is detected by a standardized neuropsychological test. According to Jak et al. (2009) MCI typically requires >1 standard deviation (SD) deficit in any cognitive domain or test as opposed to stricter criteria of at least 1.5 SD on specific tests, usually memory tests.

The working group of the Subjective Cognitive Decline Initiative (SCD-I) proposed the term “Subjective Cognitive Decline” (SCD) to define a self-experienced persistent -over a >6 months period- decline in a previously intact cognitive ability that cannot be detected on standardized neuropsychological tests and is not related to an acute event. According to them the criteria for MCI are: a) Clinical Dementia Rating (CDR) ≥0.5 or a Global Deterioration Scale stage 3 or more, or a neuropsychological profile...
indicating MCI; b) Deficit of >1.5 SD on a single test currently used in studies to define MCI (e.g., an episodic memory test); or c) Deficit of >1.0 SD on two tests within one cognitive domain or of three single tests in three different domains. Furthermore, in order to put the term SCD to practical use with regard to activities of daily living, basic and instrumental (ADL/IADL), the group suggested that SCD manifests as a perception of decrease in the mastery of performing a task, while MCI may mean a subtle functional decline without clear impairment.

**Screening for cognitive impairment**

The gold standard for identifying cognitive decline is a full neuropsychological assessment, ergo cognitive status is usually evaluated by brief assessment tools including a series of tasks completed by the patient, scored as correct or incorrect, and by rating scales for the identification and staging of cognitive decline based on information acquired during a review.

A successful neuropsychological screening test for cognitive impairment is statistically robust (high sensitivity, specificity and high predictive value), easy, and quick to administer. It doesn’t favour memory disorders over other cognitive domains, but should be able to discriminate all dementia types in unselected populations and cover six core domains: attention/working memory, new verbal learning and recall, expressive language, visual construction, executive function and abstract reasoning. Screens could be administered directly to patients, or be partly or fully informant rated.

However, the screening for SCD holds major difficulties because most of the available assessment tools focus on the memory domain contrary to the concept that SCD assessment must not be limited to memory when dealing with non-AD dementias or not typical forms of AD. The most widely known screening tool measuring cognition is the Mini-Mental State Examination (MMSE), firstly published in 1975 which includes attention/working memory, new verbal learning and recall, expressive language and visual construction tasks. One of MMSE’s limitations is its inadequacy to identify mild cognitive impairment.

In order to overcome the MMSE’s limitations, other screening tools have been proposed such as the Cognitive Abilities Screening Instrument (CASI) which is a 40-item 100-point test and The Modified Mini-Mental State Examination (3MS). Both examine all 6-core domains. The 3MS is basically an expanded MMSE test with an extended scoring procedure toward achieving better discrimination ability among individuals, specifically the discrimination of MCI from intact cognition.

On the other hand, a meta-analysis suggested that the new version of Addenbrooke’s Cognitive Examination (ACE), the ACE-R, which focuses on all core domains minus reasoning/judgment, was suitable for both primary and secondary/tertiary care settings being slightly superior to the MMSE.

The Abbreviated Mental Test Score (AMTS) is a 3–4 min 10-items test focused on orientation, registration, recall and concentration, but with low positive predictive value. It is useful in primary care where it was found superior to the MMSE for case finding, but inferior for screening.

The Clock drawing test entails the drawing of a clock face that shows the time requested, and has become a part of numerous cognitive screening batteries, e.g., Mini-Cog. Initially it was used for screening for dementia, but later for detecting more subtle disorders connected to executive function. The Mini-Cog integrates the clock-drawing test, and a word recall task into a 3 min test. It has shown approximate sensitivity and specificity to MMSE, and is suitable for screening in primary care, or settings with a higher prevalence of dementia. The General Practitioner assessment of Cognition (GPCOG) is an efficient tool for dementia screening in primary care settings consisting of two sections: the patient and the informant section. The first section includes a nine item cognitive test, whereas the second includes eight history related questions. The Montreal Cognitive Assessment (MOCA), is a 10-minute cognitive test developed for the detection of MCI, and a useful tool in screening for dementia due to vascular impairment. The DemTect Scale is a neuropsychological screening test for MCI and early dementia including the following tasks: repeating a word list, number transcoding, word fluency, digit span and delayed word list. As mentioned, in addition to the neuropsychological tests there are also staging systems of cognitive decline in which a specific, structured interview is not a prerequisite for their procedure. The Clinical Dementia Rating scale is a five-point scale assessing 6 categories of cognitive and daily function usually affected in the dementia of the Alzheimer type: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Depending on the final score the subjects are classified as: no dementia (CDR:0), questionable (CDR:0.5), mild (CDR:1), moderate (CDR:2), and severe (CDR:3) dementia.

The Global Deterioration Scale (GDS), as CDR, is also used for the assessment and classification of a subject’s cognitive function, largely interested in memory dysfunction and daily living disabilities.

**Evidence for the relationship between cognitive impairment and physical frailty**

Despite the lack of a gold standard screening tool for frailty, there are various studies across the world that explore the role of cognitive disorders within the frailty domain, presenting an heterogeneity in the methods measuring both frailty and cognitive assessment.

1. **Cross-sectional studies.** In community dwelling French people, aged 65-95, frailty status was associated with more subjective cognitive complains and depressive symptoms than pre frailty and normal status. Cognitive impairment was also detected in 39% of frail,
22% of pre-frail and 16% of robust population aged 65+ in a poor area of Sao Paulo. MMSE screening identified frail older adults with significantly lower performance in Time Orientation and Immediate Memory. In Spain, community dwelling adults aged 75+ were classified as frail and robust, found to have cognitive impairment at a percentage of 20% and 5.3%. In Japan, older women aged 65+ classified as frail, were prone to cognitive decline, as measured by MMSE, in a study searching the relationship between frailty and related factors. In a clinical setting, 65+ year old participants, admitted to the Toulouse frailty day hospital, were examined for frailty and cognitive disorder. Physical frailty was found in 51% of the cognitively impaired patients versus 38% of the patients with normal cognition, with gait speed being more related to cognitive impairment. In Korea, older adults with frailty, living in a rural community, were more likely to have poorer cognitive functioning, as well as in China, where frail participants performed worse on global cognition in all cognitive domains than their robust and pre frail counterparts. Additionally, Frailty Syndrome correlated with reduced cognitive ability in two Brazilian cities. Pre frailty with worse memory and processing speed performance, while Subjective Cognitive decline may soundly indicate frailty in the otherwise unimpaired elders. In all studies the cognitive failing interacted with frailty among other factors like age, sex, lower education, comorbidity and depressive symptoms.

**b) Longitudinal studies.** MMSE screening identified frail older adults with significantly lower performances in Time Orientation and Immediate Memory. A study assessing elders with frailty that accelerates concluded to them having a higher risk of developing Alzheimer’s Disease. The level and the rate of this happening influences the rate of cognitive decline. In frail older Mexican Americans, a score of at least 21 on MMSE (mini mental test examination) at baseline was an independent predictor of a deteriorating cognitive function over a 10-year period. Also, frail people who at baseline were normal, except in the domain of perceptual speed, in annual follow ups during a 12 year period, were found to be at high risk of developing MCI, showing a more rapid decline in episodic/semantic memory, working memory and visuospatial ability, in addition to the perceptual speed, and sooner than non frail people. Correspondingly, a four-year prospective study demonstrated frail older adults without cognitive impairment at baseline, nevertheless developing cognitive decline over a four year period. In 2012, community dwelling participants in Japan aged 70+ with Subjective cognitive changes at baseline, were significantly associated with development of frailty at follow up. In the same year, the results of a three-City Study identified cognitive impairment as a major factor contributing in future disability, whereas frailty showed inconsiderable association with non AD dementia, non association with incident Alzheimer’s disease, yet being frail independently collaborated with incident VaD, in contrast with Boyle et al findings. Similarly, in Seattle, in a population based sample of people over 65 years old, frailty was associated with 16 year incidence of non-AD dementia. These results are in accord with another study, that demonstrated a higher rate of overall and particularly VaD dementia in frail individuals. Mapt trial examined cognitive capacity in association with frailty syndrome, showing a lower level of cognitive functioning in frailty status than pre frailty. Frail older subjects scored worse at executive and attention tests, contrary to cognitively impaired subjects without frailty, plus presented a different subcortico-frontal cognitive model than those with Alzheimer Disease. In recent years, a model of reversible cognitive frailty has been proposed represented by physical frailty and self-reported cognitive decline to predict overall dementia, particularly VaD. In conclusion, cognitive deterioration seems to be strongly related to Frailty Syndrome, but whether it precedes or results from the latter is not certain. Some studies present cognitive decline as an outcome of physical frailty, an opinion which coincides with a meta-analysis that examined the mean cognitive profile of frail and pre frail participants, assessed in observational, cohort and cross-sectional studies. This study indicated the decreasing cognition to be a probable outcome of frailty, while other suggest that cognitive failure may be an early sign of frailty.

**Pathophysiology of cognitive frailty**

Although cognitive frailty is considered a multi-factorial and hence complex phenomenon, several mechanisms are known to participate in its pathophysiology.

**Neuropathological factors:** Substantia nigra neurofibrillary tangle were linked to gait speed, and frailty was associated by AD pathology, in people with or without dementia, but these findings conflict with other studies, that link frailty to non AD dementia and non amnestic cognitive impairment.

**Vascular factors:** vascular damage can reduce blood flow to the cerebrum, skeletal muscles, and heart and may have an effect in the pathophysiology of geriatric syndromes like frailty and cognitive impairment, perhaps through arterial blood pressure (BP), which coordinates tissue perfusion. Cardiovascular deficits predict frailty, as well as cardiovascular disease and cognitive decline. Cognitive vascular disorder represents a part of a group with different cerebrovascular lesions that cause cognitive impairment, and ultimately lead to dementia. Several factors that increase the risk of vascular disease can affect cognitive capacity, such as those which promote atherosclerosis and inflammation inside the vessels, and result in the reduction of blood flow.

**Inflammation:** an immune response motivated by many inflammatory mediators is associated to various
conditions, such as cardiovascular disorders, infections, rheumatological, and neuroinflammatory conditions\textsuperscript{109}. Chronic inflammation is a possible contributor to the development of frailty syndrome\textsuperscript{110} as IL-6, TNF-a and other inflammatory factors were found to increase the risk of morbidity and mortality with TNF-a and IL-6 levels identified as markers of frailty\textsuperscript{111-113}. These findings concede to a systematic review and meta-analysis, which linked frailty and pre-frailty with higher levels of inflammatory factors, particularly CRP and IL-6\textsuperscript{114}. In addition to frailty, inflammation appears to play a role in cognitive decline\textsuperscript{115}. Higher levels of IL-8 were associated with poor memory performance, processing speed and motor function (Baune et al., 2008). Inflammatory markers have also been found in the cerebrospinal fluid of patients with dementia(AD and non AD)\textsuperscript{109}. This inflammatory response is possibly managed by the microglia, resulting in neuronal damage and dysfunction\textsuperscript{116}. Contrary to the previous studies, Liu et al. (2018) suggested, that perhaps inflammation does not have a significant pathophysiological role in cognitive frailty\textsuperscript{117}.

Metabolic factors: the relationship between frailty and metabolic parameters has been explored by several researchers. In a study of older people without frailty at baseline, insulin resistance was associated with incident frailty\textsuperscript{118}, whereas four vascular risk factors (type 2 diabetes, hypertension, obesity and dyslipidemia) were related to cognitive decline, particularly type 2 diabetes and hypertension\textsuperscript{119}. In Diabetes Mellitus, hyperglycemia due to insulin resistance leads to inappropriate secretion of insulin and hyperinsulinemia. Consequently, the cells are exposed to high levels of insulin for an extended period of time, with adverse outcomes especially for neurons\textsuperscript{120} resulting in cognitive impairment\textsuperscript{121}. Some authors have expanded this concept of cognitive decline to the point of referring to Alzheimer’s disease as a type 3 diabetes mellitus (T3DM), involving specific domains of the brain, and overlapping with both type 1 and type 2 DM\textsuperscript{122}. Type 2 diabetes is also associated with reduced volumes in the brain, and progressive atrophy, independent of cerebrovascular disease\textsuperscript{123}, contributing perhaps to neurodegeneration and tau pathology\textsuperscript{124}. Metabolic syndrome (MetS) was found to be associated with amnestic MCI, especially in individuals with APOE-ε4 at younger age\textsuperscript{125}. frailty and cognition\textsuperscript{126}. Similarly, midlife total cholesterol, low-density serum lipids, lipoprotein cholesterol, and triglycerides correlate with later impaired cognition, with low HDL-C being an independent risk marker for later cognitive decline.

Hormones: age related hormonal changes may have some effect in the health status decline and play a significant role in the development of frailty, by leading to sarcopenia caused by the reduction of muscle strength and mass\textsuperscript{127-131}. Dehydroepiandrosterone (DHEA), a neurosteroid of the HPA axis, is the predecessor of androgens and estrogens, and mostly exists in circulation as DHEA-S\textsuperscript{132}. Lower DHEA-S levels has been found in frail people, while higher serum DHEAS levels were associated with better working memory, with a trend toward better executive function in men. Decreased sex steroids may also be a factor in the development of frailty in men. As testosterone promotes synaptic plasticity in the hippocampus, and regulates the accumulation of amyloid beta protein, low androgen hormone levels may also have a role in cognitive dysfunction. Growth hormone (GH) level decreases with age, and is considered to be related both to frailty and cognitive impairment\textsuperscript{133}. Disruption in regulation of the hypothalamic-pituitary adrenal axis could have an adverse outcome in the cognitive function of the elderly, with respect to the relationship of hypercortisolemia with lower cognitive performance in specific domains of cognition. G ripple, the “hunger hormone” may contribute significantly to both frailty and cognitive impairment\textsuperscript{134}. A study suggested that frail women had a higher possibility of lower levels of fasting ghrelin and 120 min ghrelin\textsuperscript{135,136}, while in men with AD, metabolic alterations may be the result of reduced secretion of this hormone\textsuperscript{137}. There is a relationship between low levels of vitamin D and poor muscle performance, through molecular mechanisms of Vitamin D3 activity in muscle tissue\textsuperscript{138}, that might explain the significant role of Vit D in the development of sarcopenia, a major component of frailty\textsuperscript{139}. Hypovitaminosis D was associated with prevalent and incident frailty in older men\textsuperscript{140,141}, and with sarcopenic status in elderly women\textsuperscript{142}. Low vitamin D levels were independently associated with frailty\textsuperscript{143}. A cross-sectional study also linked 25(OH)D with performance in specific domains of cognition, in particular executive functioning and possibly information-processing speed\textsuperscript{144-146}.

Nutrition: sarcopenia includes reduced muscle mass/ strength\textsuperscript{147} and associates with pre-frailty and frailty\textsuperscript{71}. Frailty and malnutrition are distinctly related\textsuperscript{148,149}, but the lower muscle mass, a component of Frailty Phenotype, may be irrelevant to weight status\textsuperscript{150}, and more related to specific or a combination of nutrients intake\textsuperscript{151}. An inadequate diet is a major cause of frailty\textsuperscript{152}. Insufficient protein consumption is one of the main nutritional deficits among frail persons\textsuperscript{153}, while a systematic review recognized the impact of energy intake and nutrient quality upon the development of the syndrome\textsuperscript{154}. Regarding the construct of cognitive frailty, sarcopenia\textsuperscript{71} and its component reduced muscle strength and/or physical performance related to non-muscle etiology, were associated with cognitive impairment\textsuperscript{155}. Lower energy and protein nutrition were found to have a negative impact on cognitive performance. Anorexia of aging, a contributor to weight loss, and cognitive decline have some peripheral and central peptides involved in their pathophysiology\textsuperscript{156}. Fatigue, linked perhaps to anemia, vitamin B12 and/or vitamin D deficiency, also associated with cognitive decline\textsuperscript{157}. Nutritional factors may affect brain health and this influence pertains to several mechanisms like oxidative stress, inflammation, and neuroinflammation\textsuperscript{158,159}. The brain vulnerability to oxidative damage\textsuperscript{160}, the influence
Cognitive frailty

of neuroinflammation, the suggested altered immune responses in the brain caused by the linked systemic chronic low-grade inflammation with obesity, aging and chronic diseases\textsuperscript{161}, plus the link between autophagy deterioration and deregulated mTOR signaling (a key regulator of autophagy) with glucose metabolism and neurodegenerative diseases, are proposed to affect the progression of cognitive decline\textsuperscript{158,159}.

**Reversible and potentially reversible cognitive frailty**

Frailty affects quality of life and reduces the lifespan. Frailty status when complicated with cognitive degeneration further jeopardizes health status. It is of the utmost importance to address frailty in a manifold manner, identifying factors that lead to successful and cost effective social care interventions\textsuperscript{162}. Approximating physical frailty and impairment in cognition together as a unique complex phenotype may be critical to forestall all cause dementia\textsuperscript{163}. Cognitive frailty is caused by physical or pre-physical frailty and encompasses two subtypes: the reversible cognitive frailty, indicated by subjective cognitive decline (SCD) and/or biomarkers of amyloid-β accumulation and neurodegeneration and the potentially reversible is MCI\textsuperscript{164}. A model of reversible cognitive frailty was identified as predictor of all-cause mortality and dementia, especially VaD\textsuperscript{93}. In non demented elders with advanced inflammation, a potentially reversible cognitive frailty model could also predict the additional risk of disability better than frailty or MCI alone\textsuperscript{92}. SCD may be a determinant of frailty in elders without apparent cognitive impairment thus being included in the assessment/detetection of frailty will help the implementation of suitable planning for the maintenance of healthy aging\textsuperscript{90}.

**Prevention and management of cognitive frailty: conclusions**

Any policy including multi-domain interventions intended to alleviate or converse cognitive frailty should consider the complicated concept of this condition\textsuperscript{17}. Multi-domain interventions may be capable of preventing cognitive frailty\textsuperscript{165}. Interventions focused on physical, nutritional, and cognitive domain were effectual in reversing frailty among community-dwelling older people. A home-based conducted intervention of physical training, nutritional, and social support helped to address malnutrition and frailty\textsuperscript{166}. A systematic review on the influences of multi-domain (physical exercise, nutritional, pharmacological, psychological, social) versus a single domain interventions on functional and cognitive status in frailty recognized limited but increasing evidence of the multi-domain approach e.g. exercise with nutritional support\textsuperscript{167}. Combined exercise training, intake of hyper-protein nutritional shakes, memory training and medication review reversed frailty measures among frail elders\textsuperscript{168}. Indicatively, a moderate exercise program was effective in the improvement of cognitive frailty\textsuperscript{19,117}. Resistance exercise training combined with additional protein intake had a positive effect on information processing speed whereas exercise training alone benefited attention and working memory in frail and pre frail individuals\textsuperscript{169}. In addition, high-speed resistance exercise training improved cognitive and physical function in cognitively frail older adults\textsuperscript{170}. A combination of Mediterranean diet with standard physical and mental exercise was hypothesized to be the best prevention against future cognitive decline\textsuperscript{158,159}. The management of under nutrition could be improved by higher energy/protein intake, physical activity and by having a less unsafe approach to glycemic targets in frail diabetic older people with respect to hypoglycemic risk\textsuperscript{171}. Evidence doesn’t yet support hormone supplementation\textsuperscript{172} but anti-cholinergic drugs may have a role in the prevention of both physical and cognitive declines\textsuperscript{173} and new treatments which affect the gut microbiota-muscle-brain axis could be useful\textsuperscript{174}. In conclusion interventions conducted in carefully chosen evidence-based circumstances advocate clinical investment in the management of frailty and its outcomes such as cognitive decline\textsuperscript{172}.

**References**

1. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-56.
2. de la Rica-Escuin M, Gonzalez-Vaca J, Varela-Perez R, Arjonilla-Garcia MD, Silva-Iglesias M, Oliver-Carbonell JL, et al. Frailty and mortality or incident disability in institutionalized older adults: the FINAL study. Maturitas. 2014;78(4):329-34.
3. Cheng MH, Chang SF. Frailty as a Risk Factor for Falls Among Community Dwelling People: Evidence From a Meta-Analysis. Journal of nursing scholarship: an official publication of Sigma Theta Tau International Honor Society of Nursing. 2011;49(5):529-36.
4. Aliberti MJR, Cenzer IS, Smith AK, Lee SJ, Yaffe K, Covinsky KE. Assessing Risk for Adverse Outcomes in Older Adults: The Need to Include Both Physical Frailty and Cognition. Journal of the American Geriatrics Society. 2019;67(3):477-83.
5. Rodrigues RAP, Phon JRS, Pontes MLF, Silva AO, Haas VJ, Santos JLF. Frailty syndrome among elderly and associated factors: comparison of two cities. Revista latino-americana de enfermagem. 2018;26:e3100.
6. Sanchez-Garcia S, Gallegos-Carrillo K, Espinel-Bermudez MC, Dooubova SV, Sanchez-Arenas R, Garcia-Pena C, et al. Comparison of quality of life among community-dwelling older adults with the frailty phenotype. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 2017;26(10):2693-703.
7. Yang F, Chen QW. Evaluation of frailty and influencing factors in old people in hospital institution: evidence for a phenotype of frailty. Medicine. 2018;97(3)1:e9634.
8. Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA. Physical frailty is associated with incident mild cognitive impairment in community-based older persons. Journal of the American Geriatrics Society. 2010;58(2):248-55.
9. Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H. The prevalence and
progression of mild cognitive impairment among clinic and community populations: a systematic review and meta-analysis. International journal of geriatric psychiatry. 2017;32(10):1595-608.

10. Ma L, Zhang L, Sun F, Li Y, Tang Z. Cognitive function in Prefrail and frail community-dwelling older adults in China. BMC geriatrics. 2019;19(1):53.

11. Ma L, Zhang L, Zhang Y, Li Y, Tang Z, Chan P. Cognitive Frailty in China: Results from China Comprehensive Geriatric Assessment Study. Frontiers in medicine. 2017;4:174.

12. Mitttski A, Sogn X, Skoog I, Broe GA, Cox JL, Gunfrlad E, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. Journal of the American Geriatrics Society. 2003;51(12):2184-9.

13. Rockwood K, Song X, Macknight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-95.

14. Gobbens RJ, Luijx KG, Wijten-Sponselee MT, Schols JM. Toward a conceptual definition of frail community dwelling older people. Nursing outlook. 2010;58(2):76-86.

15. Gobbens RJ, Schols JM, van Assen MA. Exploring the efficiency of the Tilburg Frailty Indicator: a review. Clinical interventions in aging. 2017;12:1739-52.

16. Gobbens RJ, van Assen M. Associations between multidimensional frailty and quality of life among Dutch older people. Archives of gerontology and geriatrics. 2017;73:69-76.

17. Kelaiditi E, Cosan M, Canevelli M, van Kan GA, Ouisset PJ, Gillette-Guyonnet S, et al. Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. The journal of nutrition, health & aging. 2013;17(9):726-34.

18. Yu R, Morley JE, Kwok T, Leung J, Cheung O, Wao J. The Effects of Combinations of Cognitive Impairment and Pre-frailty on Adverse Outcomes from a Prospective Community-Based Cohort Study of Older Chinese People. Frontiers in medicine. 2018;5:50.

19. Liu LK, Chen CH, Lee WJ, Wu YH, Hwang AC, Lin MH, et al. Cognitive Frailty and Its Association with All-Cause Mortality Among Community-Dwelling Older Adults in Taiwan: Results from H-Lan Longitudinal Aging Study Rejuvenation research. 2018;21(6):510-7.

20. Shimoda H, Doi T, Lee S, Makizako H, Chen LK, Azai H. Cognitive Frailty Predicts Incident Dementia among Community-Dwelling Older People. Journal of clinical medicine. 2018;7(9).

21. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the genericndrome of frailty. Aging clinical and experimental research. 2004;16(2):153-7.

22. Wibulblad B, Palmer K, Kivipetle M, Jelic V, Fatigioni L, Wahlund LO, et al. Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of internal medicine. 2004;256(3):240-6.

23. Jicha GA, Rentz DM. Cognitive and brain reserve and the diagnosis and treatment of preclinical Alzheimer disease. Neurology. 2013;80(13):1180-1.

24. Rentz DM, Parra Rodriguez MA, Amargio R, Stern Y, Sperling R, Ferris S. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review. Alzheimer’s research & therapy. 2013;5(6):58.

25. Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, Salmon DP. Neuropsychological contributions to the early identification of Alzheimer’s disease. Neuropsychology review. 2008;18(1):73-90.

26. Jak AJ, Bangen KJ, Wierenga CE, Delano-Wood L, Corey-Bloom J, Bondi MW. Contributions of neuropsychology and neuroimaging to understanding clinical subtypes of mild cognitive impairment. International review of neurobiology. 2009;84:1-103.

27. Jak AJ, Bondi MW, Delano-Wood L, Wierenga C, Corey-Bloom J, Salmon DP, et al. Quantification of five neuropsychological approaches to defining mild cognitive impairment. The American journal of geriatric psychiatry - official journal of the American Association for Geriatric Psychiatry. 2009;17(5):368-75.

28. Jak AJ, Urban S, McCauley A, Bangen KJ, Delano-Wood L, Corey-Bloom J, et al. Profile of hippocampal volumes and stroke risk varies by neuropsychological definition of mild cognitive impairment. Journal of the International Neuropsychological Society. 2009;15(6):890-7.

29. Ellis JA, Orr L, Li PC, Anderson RC, Feldstein NA, Meyers PM. Cognitive and functional status after vein of Galen aneurysmal malformation endovascular occlusion. World journal of radiology. 2012;4(3):83-9.

30. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. International psychogeriatrics. 2009;21(4):672-87.

31. Jessen F. Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease. European archives of psychiatry and clinical neuroscience. 2014;264 Suppl 1:S3-7.

32. Jessen F. [Mild neurocognitive disorder - a disease? For]. Der Nervenarzt. 2014;85(5):630-1.

33. Jessen F, Amargio RE, vanBokstel M, Breteler M, Ceccaldi M, Chetelat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2014;10(6):844-52.

34. Jessen F, Dodel R. [Prediction of Alzheimer’s dementia]. Der Nervenarzt. 2014;85(10):1233-7.

35. Jessen F, Wolszczbruber S, Weise B, Bickel H, Mosch E, Kadoszkiewicz H, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2014;10(1):76-83.

36. Molinuevo JL, Rabin LA, Amargio R, Buckley R, Dubois B, Ellis KA, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2017;13(3):296-311.

37. Salmon DP, Bondi MW. Neuropsychological assessment of dementia. Annual review of psychology. 2009;60:257-82.

38. Cullen B, O’Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive impairment. Journal of nutrition, neurosurgery, and psychiatry. 2007;78(8):790-9.

39. Scheltens NM, Galindo-Garre F, Pijnenburg YA, van der Vlies AE, Smits LL, Koenne T, et al. The identification of cognitive subtypes in Alzheimer’s disease dementia using latent class analysis. Journal of the International Neuropsychological Society : JINS. 2009;15(3):296-303.

40. Burns A, Brayne C, Folstein M. Key Papers in Geriatric Psychiatry: a comprehensive review. Journal of the American Geriatric Society. 1999;42(9):922-35.

41. Gray SL, Anderson ML, Hubbard RA, LaCroix A, Crane PK, McCormick W, et al. Frailty and incident dementia. J Gerontol A Biol Sci Med Sci. 2013;68(9):1083-90.
Cognitive frailty

43. Brandt J, Benedict RH. Hopkins verbal learning test--revised: professional manual. Psychological Assessment Resources; 2001.

44. VanPatten RB, Britton K, Tremont G. Comparing the Mini-Mental State Examination and the modified Mini-Mental State Examination in the detection of mild cognitive impairment in older adults. International psychoenergetics. 2019;3(15):693-701.

45. Lamer AJ, Mitchell AJ. A meta-analysis of the accuracy of the Addenbrooke's Cognitive Examination (ACE) and the Addenbrooke's Cognitive Examination-Revised (ACE-R) in the detection of dementia. International psychoenergetics. 2014;26(4):555-63.

46. Sheehan B. Assessment scales in dementia. Therapeutic advances in neurological disorders. 2012;5(6):349-58.

47. Mitchell AJ, Malladi S. Screening and case finding tools for the detection of dementia. Part I: evidence-based meta-analysis of multidomain tests. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2010;18(9):759-82.

48. Mitchell AJ, Malladi S. Screening and case-finding tools for the detection of dementia. Part II: evidence-based meta-analysis of single-domain tests. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2010;18(9):783-800.

49. Woo BK, Rice VA, Legendre SA, Salmon DP, Jeste DV, Sewell DD. The clock drawing test as a measure of executive dysfunction in elderly depressed patients. Journal of geriatric psychiatry and neurology. 2004;17(4):190-4.

50. Vyhniak M, Rubinova E, Markova H, Nikolai T, Laczo J, Andel R, et al. Clock drawing test in screening for Alzheimer's dementia and mild cognitive impairment in clinical practice. Int J Geriatr Psychiatry. 2017;32(9):933-9.

51. Spenciere B, Alves H, Charchat-Fichman H. Scoring systems for dementia. Human genetics. 2002;110(1):8-14.

52. Brodaty H, Green A. Defining the role of the caregiver in Alzheimer’s disease treatment: Drugs & aging. 2002;19(2):891-8.

53. Brodaty H, Green A. Who cares for the carer? The often forgotten frailty index and survival in elderly Brazilians: the FIBRA Study. Cadernos de saúde publica. 2017:33(5):e00194115.

54. Moretti MC, Fontaine AM, Garcia CA, Neri AL, Guanento ME. Association between race, obesity and diabetes in elderly community dwellers: data from the FIBRA study. Cadernos de saúde publica. 2016;32(10):e00081315.

55. Morelli NL, Cachioni M, Lopes A, Batistone SST, Falcao D, Neri AL, et al. Verbal fluency in elderly with and without hypertension and diabetes from the FIBRA study in Ermelino Matarazzo. Dementia & neuropsychologia. 2017;11(4):413-8.

56. Yassuda MS, Lopes A, Cachioni M, Falcao DV, Batistone SS, Guimarães VV, et al. Frailty criteria and cognitive performance are related data from the FIBRA study in Ermelino Matarazzo, Sao Paulo, Brazil. The journal of nutrition, health & aging. 2012;16(1):55-61.

57. Maccio CR, Batistone SS, Lopes A, Cachioni M, da Silva Falcao DV, Neri AL, et al. Mini-Mental State Examination performance in frail, pre-frail, and non-frail community dwelling older adults in Ermelino Matarazzo, Sao Paulo, Brazil. International psychogeriatrics. 2012;24(11):1725-31.

58. Jurschik P, Nunin C, Botique T, Escobar MA, Lavedan A, Viladrosa M. Prevalence of frailty and factors associated with frailty in the elderly population of Lleida, Spain: the FRALLE survey. Archives of gerontology and geriatrics. 2012;55(3):625-31.

59. Nishiguchi S, Yamada M, Fukutani N, Adachi D, Tashiro Y, Hotta T, et al. Differential association of frailty with cognitive decline and sarcopenia in community-dwelling older adults. Journal of the American Medical Directors Association. 2015;16(2):120-4.

60. Fougeré B, Oustric S, Delireu J, Chicoula B, Escurrou E, Rolland Y, et al. Implementing Assessment of Cognitive Function and Frailty Into Primary Care: Data From Frailty and Alzheimer disease prevention into Primary care (FAP) Study Pilot. Journal of the American Medical Directors Association. 2017;18(1):47-52.

61. Fougeré B, Daumans M, Liïamand M, Sourdet S, Delireu J, Vellais B, et al. Association Between Frailty and Cognitive Impairment: Cross-Sectional Data From Toulouse Frailty Day Hospital. Journal of the American Medical Directors Association. 2017;18(11):990 e1-e5.

62. Fougeré B, Delireu J, Del Campo N, Soniano G, Sourdet S, Vellais B. Cognitive Frailty: Mechanisms, Tools to Measure, Prevention and Controversy. Clinics in geniatric medicine. 2017;33(3):339-55.

63. Fougeré B, Morley JE. Editorial: Weight Loss is a Major Cause of Frailty. The journal of nutrition, health & aging. 2017;21(9):933-5.
76. Fougere B, Sourdet S, Lilamand M, Tabue-Tequod M, Teyssseyre B, Dupuy C, et al. Untangling the overlap between frailty and low lean mass. Data from Toulouse frailty day hospital. Archives of gerontology and geriatrics. 2018;75:209-13.

77. Yoon DH, Hwang SS, Lee DW, Lee CO, Song W. Physical Frailty and Cognitive Functioning in Korean Rural Community-Dwelling Older Adults. Journal of clinical medicine. 2018;7(11).

78. Poon JR, Rodrigues RA, Santos JLF, Diniz MA, Santos EBD, Almeida VC, et al. Factors associated with frailty in older adults: a longitudinal study. Revista de saude publica. 2018;52:74.

79. Umegaki H, Makino T, Shimada H, Hayashi T, Wu Cheng X, Kuzuya M. Cognitive Dysfunction in Urban-Community Dwelling Pre frail Older Subjects. The journal of nutrition, health & aging. 2018;22(4):549-54.

80. Margioli E, Kosmidis MH, Yannakoula M, Dardiotis E, Hadjigeorgiou G, Sakka P, et al. Exploring the association between subjective cognitive decline and frailty: the Hellenic Longitudinal Investigation of Aging and Diet Study (HELIAAD). Aging & mental health. 2019;1-11.

81. Boyle PA, Wilson RS, Buchman AS, Aggarwal NT, Tang Y, Arvanitakis Z, et al. Lower extremity motor function and disability in mild cognitive impairment. Experimental aging research. 2007;33(3):355-71.

82. Buchman AS, Boyle PA, Wilson RS, Tang Y, Bennett DA. Frailty is associated with incident Alzheimer’s disease and cognitive decline in the elderly. Psychosomatic medicine. 2007;69(5):483-9.

83. Buchman AS, Wilson RS, Boyle PA, Flarschman DA, Bennett DA. Physical activity and leg strength predict decline in mobility performance in older persons. Journal of the American Geriatrics Society. 2007;55(10):1618-23.

84. Samper-Torrent R, Al Sihni S, Raji MA, Markides KS, Ottenbacher KJ. Relationship between frailty and cognitive decline in older Mexican Americans. Journal of the American Geriatrics Society. 2008;56(10):1845-52.

85. Auyeung TW, Lee JS, Kwok T, Leung J, Ohlsson C, Vandenput L, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1,489 older men. European journal of endocrinology. 2011;164(S):811-7.

86. Auyeung TW, Lee JS, Kwok T, Woo J. Physical frailty predicts future cognitive decline - a four-year prospective study in 2,737 cognitively normal older adults. The journal of nutrition, health & aging. 2011;15(8):690-4.

87. Lee JS, Auyeung TW, Leung J, Kwok T, Leung PC, Woo J. Physical frailty in older adults is associated with metabolic and atherosclerotic risk factors and cognitive impairment independent of muscle mass. The journal of nutrition, health & aging. 2011;15(10):857-62.

88. Avila-Funes JA, Carcailton L, Heilm C, Carniere I, Ritche K, Rouaud O, et al. Is frailty a prodromal stage of vascular dementia? Results from the Three-City Study. Journal of the American Geriatrics Society. 2012;60(9):1708-12.

89. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age (Dordrecht, Netherlands). 2013;35(2):441-53.

90. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Maggi S, et al. Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging. Alzheimer's & dementia : the journal of the American Alzheimer's Disease Association. 2017;13(8):1829-37.

91. Deineux J, Andrieu S, Pahor M, Cantet C, Cesari M, Ouisset PJ, et al. Neuropsychological Profile of “Cognitive Frailty” Subjects in MAPT Study. The journal of prevention of Alzheimer's disease. 2016;3(3):151-9.

92. Solfrizzi V, Scafato E, Lozupone M, Seripa D, Giannini M, Sardone R, et al. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2017;25(1):1236-48.

93. Solfrizzi V, Scafato E, Seripa D, Logroscino M, Imbimbo BP, D’Amato A, et al. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging. Journal of the American Medical Directors Association. 2017;18(1):89 e1- e8.

94. Furtado GE, Letieri R, Hogervorst E, Teixeira AB, Ferreira JP. Physical Frailty and cognitive performance in older populations, part I: systematic review with meta-analysis. Ciencia & saude coletiva. 2019;24(1):203-18.

95. Gade CR, Ritchie SJ, Cooper C, Starr JM, Deary IJ. Cognitive Ability in Late Life and Onset of Physical Frailty: The Lothian Birth Cohort 1936. Journal of the American Geriatrics Society. 2017;65(6):1289-95.

96. Volkert D, Bemer VN, Berry E, Cederholm T, Coti Bertrand P, Milne AL, et al. ESPEN Guidelines on Enteral Nutrition: Genetitics. Clinical nutrition (Edinburgh, Scotland). 2006;25(2):330-60.

97. Buchman AS, Schneider JA, Leurgans S, Bennett DA. Physical frailty in older persons is associated with Alzheimer disease pathology. Neurology. 2008;71(7):499-504.

98. Panza F, Solfrizzi V, Frisardi V, Maggi S, Sancarlo D, Adante F, et al. Different models of frailty in predementia and dementia syndromes. The journal of nutrition, health & aging. 2011;15(8):711-9.

99. Solfrizzi V, Scafato E, Frisardi V, Sancarlo D, Seripa D, Logroscino G, et al. Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging. Age (Dordrecht, Netherlands). 2012;34(2):507-17.

100. Ahmed N, Mandela R, Fain MJ. Frailty: an emerging geriatric syndrome. The American journal of medicine. 2007;120(9):748-53.

101. Bouillon K, Kivimaki M, Hamer M, Sabia S, Fransson EI, Singh-Manoux A, et al. Measures of frailty in population-based studies: an overview. BMC geriatrics. 2013;13:64.

102. Bouillon K, Kivimaki M, Hamer M, Shipley MJ, Akbaraly TN, Tabak A, et al. Diabetes risk factors, diabetes risk algorithms, and the prediction of future frailty: the Whitehall II prospective cohort study. Journal of the American Medical Directors Association. 2013;14(11):851 e1- e6.

103. Bouillon K, Sabia S, Jokela M, Gale CR, Singh-Manouxx A, Shipley MJ, et al. Validating a widely used measure of frailty: are all sub-components necessary? Evidence from the Whitehall II cohort study. Age (Dordrecht, Netherlands). 2013;35(4):1457-65.

104. Fattori A, Santimaria MR, Alves RM, Guariento ME, Neri AL. Inflow of blood pressure profile on frailty phenotype in community-dwelling elders in Brazil - FIBRA study. Archives of gerontology and geriatrics. 2013;56(2):343-49.

105. de la Torre JC. The vascular hypothesis of Alzheimer’s disease: bench to bedside and beyond. Neuro-degenerative diseases. 2010;7(1-3):116-21.

106. de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer’s disease. Ageing research reviews. 2010;9(3):218-25.

107. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Uğur Z, et al. Assessment of endothelial function in Alzheimer’s disease: is it a vascular disease? Journal of the American Geriatrics Society. 2007;55(10):1613-7.

108. Bouillon K, Kivimaki M, Hamer M, Sabia S, Fransson EI, Singh-Manoux A, et al. Neuropsychological Profile of “Cognitive Frailty” Subjects in MAPT Study. The journal of prevention of Alzheimer's disease. 2016;3(3):151-9.
Cognitive frailty

109. Corelick PB. Role of inflammation in cognitive impairment: results of observational epidemiological studies and clinical trials. Annals of the New York Academy of Sciences. 2010;1207:155-62.

110. Wong HS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al. Response to letter regarding article, “early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis”. Circulation. 2014;130(8):e74.

111. Hubbard RE, Woodhouse KW. Frailty, inflammation and the elderly. Biogerontology. 2010;11(5):635-41.

112. Leng S, Chaves P, Koening K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. Journal of the American Geriatrics Society. 2002;50(7):1268-71.

113. Michaud M, Balardti L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory cytokines, aging, and age-related diseases. Journal of the American Medical Directors Association. 2013;14(12):877-82.

114. Soysal P, Stubbs B, Lucato R, Chirni C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: A systematic review and meta-analysis. Ageing research reviews. 2016;31:1-8.

115. Mulero J, Zafilla P, Martinez-Cacha A. Oxidative stress, frailty and cognitive decline. The journal of nutrition, health & aging. 2011;15(9):756-60.

116. Cunningham EL, Passmore AP. Drug development in dementia. Maturitas. 2013;76(3):260-6.

117. Liu Z, Hsu FC, Trombetti A, King AC, Liu CK, Manini TM, et al. Effect of 24-month physical activity on cognitive frailty and the role of inflammation: the LIFE randomized clinical trial. BMC medicine. 2018;16(1):185.

118. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007;167(7):635-41.

119. van den Berg E, Klokpenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition. Biochimica et biophysica acta. 2009;1792(5):470-81.

120. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: A systematic comparison of their impact on cognition. Biochimica et biophysica acta. 2009;1792(5):470-81.

121. Zhong Y, Miao Y, Jia WP, Yan H, Wang BY, Jin J. Hyperinsulinemia, insulin resistance and cognitive decline in older cohort: Biomedical and environmental sciences. BES. 2012,25(1):8-14.

122. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes—evidence reviewed. Journal of diabetes science and technology. 2008;2(6):1101-13.

123. Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer’s disease a Type 3 Diabetes? A critical appraisal. Biochimica et biophysica acta Molecular basis of disease. 2017;1863(5):1078-89.

124. Sutherland GT, Lim J, Srikarth V, Bruce DG. Epidemiological Approaches to Understanding the Link Between Type 2 Diabetes and Dementia. Journal of Alzheimer’s disease : JAD. 2017;59(2):393-403.

125. Feng L, Chong MS, Lim WS, Lee TS, Collinson SL, Yap P, et al. Metabolic syndrome and amnestic mild cognitive impairment: Singapore Longitudinal Ageing Study-2 Findings. Journal of Alzheimer’s disease : JAD. 2013;33(4):649-57.

126. Lin F, Roland R, Chen DG, Oiu C. Linking cognition and frailty in middle and old age: metabolic syndrome matters. Int J Geriatr Psychiatry. 2015;30(1):64-71.

127. Malmstrom TK, Morley JE. Frailty and cognition: linking two common syndromes in older persons. The journal of nutrition, health & aging. 2013;17(9):723-5.

128. Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. Journal of the American Medical Directors Association. 2013;14(6):531-2.

129. Malmstrom TK, Morley JE. The frail brain. Journal of the American Medical Directors Association. 2013;14(7):453-5.

130. Malmstrom TK, Morley JE. Sarcopenia: The Target Population. The journal of frailty & aging. 2013;2(1):55-6.

131. Morley JE, Malmstrom TK. Frailty, sarcopenia, and hormones. Endocrinology and metabolism clinics of North America. 2013;42(2):391-405.

132. Powrie YSL, Smith C. Central intracrine DHEA synthesis in age-related neuroinflammation and neurodegeneration: therapeutic potential? Journal of neuroinflammation. 2018;15(1):289.

133. Nass R, Thomer MO. Impact of the GH-cortisol ratio on the age-dependent changes in body composition. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2002;12(3):147-61.

134. Serra-Prat M, Palomera E, Clave P, Puig-Domingo M. Effect of age and frailty on ghrelin and cholecystokinin responses to a meal test. The American journal of clinical nutrition. 2009;89(5):1410-7.

135. Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR. Frailty status and altered glucose-insulin dynamics. J Gerontol A Biol Sci Med Sci. 2012;67(12):1300-6.

136. Kalyani RR, Varadhan R, Weiss CO, Fried LP, Cappola AR. Frailty status and altered dynamics of circulating energy metabolism hormones after oral glucose in older women. The journal of nutrition, health & aging. 2012;16(8):679-86.

137. Theodoropoulou A, Metallinos IC, Psyriariannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer’s disease. The journal of nutrition, health & aging. 2012;16(5):472-7.

138. Ceglia L, Harns SS. Vitamin D and its role in skeletal muscle. Calcified tissue international. 2013;92(2):151-62.

139. Mason C, Xiao L, Imaiama I, Duggan CR, Foster-Schubert KE, Kong A, et al. Influence of diet, exercise, and serum vitamin d on sarcopenia in postmenopausal women. Medicine and science in sports and exercise. 2013;45(4):607-14.

140. Wong YY, Flicker L, Yeap BB, McCaul KA, Hankey GJ, Norman PE. Is hypovitaminosis D associated with abdominal aortic aneurysm, and is there a dose-response relationship? European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2013;45(6):657-64.

141. Wong YY, McCaul KA, Yeap BB, Hankey GJ, Flicker L. Low vitamin d status is an independent predictor of increased frailty and all-cause mortality in older men. The Health in Men Study. The Journal of clinical endocrinology and metabolism. 2013;98(9):3821-8.

142. Anagnostis P, Dimopoulou C, Karras S, Lambrinoudaki I, Goulis DG. Sarcopenia in post-menopausal women: Is there any role for vitamin D? Maturitas. 2015;82(1):56-64.

143. Hirani V, Cumming RG, Naganathan V, Blyth F, Le Couteur DG, Handelsman DJ, et al. Associations between serum 25-hydroxyvitamin D concentrations and multiple health conditions, physical performance measures, disability, and all-cause mortality: the Concord Health and Ageing in Men Project. Journal of the American Geriatrics Society. 2014;62(3):417-25.

144. Brouwer-Brolsma EM, Bischoff-Ferrari HA, Bouillon R, Feskens EJ, Gallagher CJ, Hypponen E, et al. Vitamin D: do we get enough? Journal of the American Medical Directors Association. 2014;15(3):185-9.
as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013;24(5):1567-77.

145. Brouwer-Brolsma EM, Feskens EJ, Steegenga WT, de Groot LC. Associations of 25-hydroxyvitamin D with fasting glucose, fasting insulin, dementia and depression in European elderly: the SENECA study. European journal of nutrition. 2013;52(3):917-25.

146. Brouwer-Brolsma EM, van de Rest O, Tieland M, van der Zwaluw NL, Steegenga WT, Adam JJ, et al. Serum 25-hydroxyvitamin D is associated with cognitive executive function in Dutch prefrail and frail elderly: a cross-sectional study exploring the associations of 25-hydroxyvitamin D with glucose metabolism, cognitive performance and depression. Journal of the American Medical Directors Association. 2013;14(1):852 e9-17.

147. Xue QL. The frailty syndrome: definition and natural history. Clinics in geriatric medicine. 2011;27(1):1-15.

148. Wei K, Nyunt MS, Gao Q, Wee SL, Yap KB, Ng TP. Association of Frailty and Malnutrition With Long-term Functional and Mortality Outcomes Among Community-Dwelling Older Adults: Results From the Singapore Longitudinal Aging Study 1. JAMA network open. 2018;1(3):e180650.

149. Wei K, Nyunt MS, Gao Q, Wee SL, Ng TP. Frailty and Malnutrition Related and Distinct Syndrome Prevalence and Association Among Community-Dwelling Older Adults: Singapore Longitudinal Ageing Studies. Journal of the American Medical Directors Association. 2017;18(12):1019-28.

150. Sao Romao Preto L, Dias Conceicao MDC, Figueiredo TM, Pereira Mata MA, Barreiro Preto PM, Mateo Aguilar E. Frighty, body composition and nutritional status in non-institutionalised elderly. Enfermagem clinica. 2017;27(6):339-45.

151. Yannakoulia M, Ntanasi E, Anastasiou CA, Scarmeas N. Frailty and nutrition: From epidemiological and clinical evidence to potential mechanisms. Metabolism: clinical and experimental. 2017;68:64-76.

152. Goisser S, Guyonnet S, Volkert D. The Role of Nutrition in Frailty: An Overview. The Journal of frailty & aging. 2017;6(1):72-3.

153. Domínguez LJ, Barbagallo M. Perspective: Protein supplementation in frail older persons: often necessary but not always sufficient. The Journal of frailty & aging. 2016;5(2):74-7.

154. Lorenzo-Lopez L, Maseda A, de Labra C, Regueiro-Folgueira L, Dominguez LJ, Barbagallo M. The relevance of nutrition for the future core business of Public Health: Report of the Activities of the A3 Action Group of the European Innovation Partnership on Active and Healthy Ageing(EIPonAHA). International Journal of environmental research and public health. 2018;15(12).

155. Panza F, Seripa D, Solfrizzi V, Tortelli R, Greco A, Pirolli A, et al. Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. Journal of Alzheimer’s disease - JAD. 2015;47(4):793-813.

156. Ruan Q, Yu Z, Chen M, Bao Z, Li J, He W. Cognitive frailty, a novel target for the prevention of elderly dependency. Ageing research reviews. 2015;20:1-10.

157. Panza F, Lozupone M, Solfrizzi V, Sardone R, Dibello V, Di Lena L, et al. Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. Journal of Alzheimer’s disease - JAD. 2016;52(3):1012.

158. Luger E, Dorner TE, Haider S, Kapan A, Lackinger C, Schindler K. Effects of a Home-Based and Volunteer-Administered Physical Training, Nutritional, and Social Support Program on Malnutrition and Frailty in Older Persons: A Randomized Controlled Trial. Journal of the American Medical Directors Association. 2016;17(7):671 e9-e16.

159. Dedeyne L, Deschodt M, Verschueren S, Tournoy J, Gielen E. Effects of multi-domain interventions in prefrail elderly on frailty, functional, and cognitive status. a systematic review. Clinical interventions in aging. 2017;12:673-96.

160. Romero-Liebana L, Orfila F, Segura JM, Real J, Fabra ML, Moller M, et al. Effects of a Primary Care-Based Multifacational Intervention on Physical and Cognitive Function in Frail, Elderly Individuals: A Randomized Controlled Trial. J Gerontol A Biol Sci Med Sci. 2018;73(12):1688-74.

161. van de Rest O, van der Zwaluw NL, Tieland M, Adam JJ, Hiddink GJ, van Loon LJ, et al. Effect of resistance-type exercise training with or without protein supplementation on cognitive functioning in frail and pre-frail elderly: secondary analysis of a randomized, double-blind, placebo-controlled trial. Mechanisms of ageing and development. 2014;136-137:85-93.

162. Yoon DH, Lee JY, Sonq W. Effects of Resistance Exercise Training on Cognitive Function and Physical Performance in Cognitive Frailty: A Randomized Controlled Trial. The journal of nutrition, health & aging. 2018;22(8):944-51.

163. Nanni H, Yamada Y, Yoshida T, Okabe Y, Nozawa Y, Iti A, et al. Sex Difference in the Association Between Protein Intake and Frailty: Assessed Using the Kihon Checklist: Indexes Among Older Adults. Journal of the American Medical Directors Association. 2018;19(9):801-5.

164. Apostolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a systematic review. JBI database of systematic reviews and implementation reports. 2018;16(1):140-232.

165. Sargent L, Nalls M, Amelka EJ, Mueller M, Lageman SK, Bandinelli S, et al. Anticholinergic Drug Induced Cognitive and Physical Impairment: Results from the InCHIANTI Study. J Gerontol A Biol Sci Med Sci. 2020;75(5):995.

166. Buiques C, Fernandez-Garrido J, Prumhoo LM, Hoogland AJ, Navarro-Martínez R, Martinez-Martínez M, et al. Effect of a Prebiotic Formulation on Frailty Syndrome: A Randomized, Double-Blind Clinical Trial. International journal of molecular sciences. 2016;17(6):932.